This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Innovations in Maternal, Neonatal, and Early Infancy Vaccines

Innovations in Maternal, Neonatal, and Early Infancy Vaccines

Tuesday, June 23, 2020, 8:05 AM - 6:30 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

 

Maternal, neonatal, and early infancy vaccines have the potential to significantly improve the health of mothers and children worldwide by reducing morbidity and mortality from diseases that are a risk to individuals early in life, and for which no alternative effective preventive strategies exist.  Although several existing vaccines have been shown to be safe and effective for use during pregnancy, there are no vaccines formally approved or licensed specifically for use in pregnant women.  Active research is taking place, with substantial progress continually made.  It is believed that licensure of new vaccines exclusively for use in pregnant woman to protect their newborns and infants will soon be an attainable goal.

This one-day scientific symposium spans basic science, clinical, epidemiological, translational, and policy research, and will provide a neutral forum to explore recent achievements and challenges in the development and licensure of novel maternal vaccines, as well as the utilization of currently licensed vaccines during pregnancy.  Through a series of keynote and plenary presentations, major themes on the program include: maternal-fetal immunology and physiology; lessons learned from vaccines currently used in pregnancy; new targets for maternal, neonatal, and early infancy immunization; and maternal immunization barriers to uptake.

Call for Abstracts

Abstract submissions are invited for a poster session. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Monday, April 13, 2020.

Registration

Member
By 05/11/2020
$90
After 05/11/2020
$130
Nonmember Academia, Faculty, etc.
By 05/11/2020
$180
After 05/11/2020
$260
Nonmember Corporate, Other
By 05/11/2020
$250
After 05/11/2020
$350
Nonmember Not for Profit
By 05/11/2020
$180
After 05/11/2020
$260
Nonmember Student, Undergrad, Grad, Fellow
By 05/11/2020
$100
After 05/11/2020
$145
Member Student, Post-Doc, Fellow
By 05/11/2020
$50
After 05/11/2020
$70
Earlybird Registration:
103
days
left
Deadline:
75
days
left

Organizers

Annaliesa Anderson, PhD
Annaliesa Anderson, PhD

Pfizer

Gregory Glenn, MD
Gregory Glenn, MD

Novavax

Emmanuel Hanon
Emmanuel Hanon, PhD

GlaxoSmithKline

Wayne Koff
Wayne Koff, PhD

The Human Vaccines Project

Stanley Plotkin
Stanley Plotkin, MD

Vaxconsult LLC, University of Pennsylvania

Melanie Brickman Borchard, PhD, MSc
Melanie Brickman Borchard, PhD, MSc

New York Academy of Sciences

George Zavoico, PhD
George Zavoico, PhD

Senior Equity Analyst

Speakers

Barney Graham
Barney Graham, MD, PhD

National Institute of Allergy and Infectious Diseases (NIAID), NIH

Ruth Karron, MD
Ruth Karron, MD

Johns Hopkins Bloomberg School of Public Health

Kirsty Le Doare
Kirsty Le Doare, MD, PhD

St. George’s, University of London

Janet Englund
Janet Englund, MD

Seattle Children’s Hospital

Ofer Levy, MD, PhD
Ofer Levy, MD, PhD

Boston Children's Hospital; Harvard Medical School

Noel T. Mueller, PhD
Noel T. Mueller, PhD

Johns Hopkins University

Lenore Pereira, PhD
Lenore Pereira, PhD

University of California, San Francisco

Arnaud Marchant, MD, PhD
Arnaud Marchant, MD, PhD

Institute for Medical Immunology (IMI), Université Libre de Bruxelles

Ajoke Sobanjo-ter Meulen
Ajoke Sobanjo-ter Meulen, MD, MSc

Bill & Melinda Gates Foundation

Tuesday

June 23, 2020

8:05 AM

Registration, Breakfast, and Poster Setup

8:45 AM

Welcome Remarks

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
8:55 AM

Keynote Presentation

Speaker

Speaker to be announced

SESSION I: Maternal-Fetal Immunology and Physiology

Session Chairperson
Gregory Glenn, MD, Novavax
9:30 AM

Transplacental Antibody Transfer Following Maternal Immunization

Speaker

Arnaud Marchant, MD, PhD
Institute for Medical Immunology (IMI), Université Libre de Bruxelles
9:55 AM

Impact of Maternal Microbiota on Infant Microbiota and Development

Speaker

Noel T. Mueller, PhD
Johns Hopkins University
10:20 AM

Networking Coffee Break

10:50 AM

Antibody Transfer from Mother to Infant: The Physiology of Breast Milk

Speaker

Kirsty Le Doare, MD, PhD
St. George’s, University of London
11:15 AM

The Structure of the Human Placenta Enables Humoral and Cellular Immune Defense

Speaker

Lenore Pereira, PhD
University of California, San Francisco

SESSION II: Lessons Learned from Current Maternal Vaccines

Session Chairperson
Stanley Plotkin, MD, Vaxconsult LLC; University of Pennsylvania
11:40 AM

Maternal Vaccines Licensed for Use in Adults: What Can Be Learned from Recent Experiences with Influenza, Pertussis, and Tetanus Vaccines

Speaker

Janet Englund, MD
Seattle Children’s Hospital

SESSION III: Data Blitz Presentations

Session Chairperson
George Zavoico, PhD
12:05 PM

Speaker to be selected from submitted abstracts

12:10 PM

Speaker to be selected from submitted abstracts

12:15 PM

Networking Luncheon

SESSION IV: New Targets for Maternal, Neonatal, and Early Infancy Immunization

Session Chairperson
Annaliesa Anderson, PhD, Pfizer
1:30 PM

Cytomegalovirus (CMV): The Direct Effect of Preventing Maternal Infection and Transmission to the Fetus

Speaker

Stanley Plotkin, MD
Vaxconsult LLC, University of Pennsylvania
1:55 PM

Progress on Developing a Maternal Pre-fusion F Vaccine for the Prevention of Neonatal RSV Disease

Speaker

Kathrin Jansen, PhD
Pfizer
2:20 PM

Learnings from a Phase 3 RSV Clinical Trial

Speaker

Gregory Glenn, MD
Novavax
2:45 PM

New Modalities in Maternal Vaccines

Speaker

Emmanuel Hanon, PhD
GlaxoSmithKline
3:10 PM

Networking Coffee Break

3:40 PM

Updates on Group B Streptococcus (GBS) Vaccine Development

Speaker

Ajoke Sobanjo-ter Meulen, MD, MSc
Bill & Melinda Gates Foundation
4:05 PM

Approaches to Infant Vaccination for RSV

Speaker

Barney Graham, MD, PhD
National Institute of Allergy and Infectious Diseases (NIAID), NIH
4:30 PM

Precision Vaccines to Shield the Young: Bringing Precision Medicine to Infant Vaccine Development

Speaker

Ofer Levy, MD, PhD
Boston Children's Hospital

SESSION V: Maternal Immunization Barriers to Uptake

Session Chairperson
Emmanuel Hanon, PhD, GlaxoSmithKline
4:55 PM

Maternal Immunization Barriers to Uptake

Speaker

Ruth Karron, MD
Johns Hopkins Bloomberg School of Public Health
5:20 PM

Closing Remarks

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
5:30 PM

Networking Reception and Poster Session

6:30 PM

End of Day